Hangzhou, China - January 10, 2025 - Hangzhou Heme Pharmaceuticals Co., Ltd. ("Heme Pharmaceuticals") and Shanghai Institute of Materia Medica, Chinese Academy of Sciences ("Shanghai Institute of Materia Medica") jointly announced today the signing of a global licensing agreement with Johnson & Johnson* to develop a potential best-in-class BTK degrader for the treatment of various diseases.Ms. Zhou Xinglu, CEO and Co-founder of Healgen Pharmaceuticals, stated:"We are delighted to collaborate with Johnson & Johnson to accelerate the development of BTK degraders. We look forward to bringing new treatment options to patients and jointly achieving the goal of rapidly developing breakthrough therapies."* Legal entity, Janssen Pharmaceutica NV
About Hezheng PharmaceuticalsHepharma is a clinical-stage small molecule innovative drug research and development company driven by innovation technology, committed to addressing unmet clinical needs. The company independently develops targeted protein degradation drugs and an intelligent drug discovery platform, focusing on drug research and development in the fields of oncology, autoimmune diseases, and central nervous system disorders.
Contact and Harmony Pharmaceuticals:About Shanghai Institute of Materia MedicaThe Shanghai Institute of Materia Medica, Chinese Academy of Sciences, established in 1932, is China's oldest comprehensive institution for innovative drug research. The institute focuses on the frontier areas of international life science development and key scientific issues in drug research, conducting fundamental and applied basic research on innovative drugs and developing new theories, methods, and technologies. It prioritizes new drug development for the treatment of cancer, cardiovascular and cerebrovascular diseases, neuropsychiatric disorders, metabolic diseases, autoimmune diseases, and infectious diseases, while also strengthening the research and development of modern traditional Chinese medicine.Follow the official account below to see the world!
